California Public Employees Retirement System Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

California Public Employees Retirement System reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 23.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 126,386 shares of the biotechnology company's stock after selling 38,071 shares during the quarter. California Public Employees Retirement System owned 0.14% of Sarepta Therapeutics worth $12,187,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock valued at $1,039,212,000 after purchasing an additional 41,465 shares during the last quarter. Picton Mahoney Asset Management acquired a new stake in Sarepta Therapeutics in the 3rd quarter worth about $2,576,000. WCM Investment Management LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at about $600,000. Capula Management Ltd acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at about $1,409,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sarepta Therapeutics by 351.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company's stock worth $1,044,000 after acquiring an additional 8,427 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares of the company's stock, valued at $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 1,200 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the sale, the chief financial officer now directly owns 39,114 shares of the company's stock, valued at $5,018,326.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $0.27 during trading hours on Thursday, hitting $130.63. The company had a trading volume of 2,082,260 shares, compared to its average volume of 1,013,894. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The firm has a market cap of $12.35 billion, a P/E ratio of -22.03 and a beta of 0.95. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The business has a fifty day simple moving average of $125.77 and a 200-day simple moving average of $110.56.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same period last year, the firm posted ($1.44) EPS. Sarepta Therapeutics's quarterly revenue was up 63.1% compared to the same quarter last year. Equities analysts predict that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on SRPT. Barclays increased their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, February 29th. TheStreet upgraded Sarepta Therapeutics from a "d" rating to a "c-" rating in a report on Monday, March 4th. BMO Capital Markets initiated coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They set an "outperform" rating and a $170.00 target price for the company. Wedbush restated an "outperform" rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $156.60.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.